CMS broadens coverage of CAR T therapies

After receiving 146 comments across two comment periods, CMS has opened up its coverage criteria for CAR Ts.

In a final National Coverage Determination issued Wednesday, the Centers for Medicare & Medicaid Services said it would cover marketed CAR T therapies for their FDA approved indications and off-label uses that are supported by CMS-approved compendia, including the National Comprehensive Cancer Network (NCCN) guidelines...